Here's the latest news from Cart.com. Photo via cart.com

In the past week, Houston-based Cart.com has made some big moves on its tech startup journey — including another strategic acquisition and new hire.

The end-to-end e-commerce-as-a-service provider, which recently raised a $98 million series B round of funding, announced Tony Puccetti as the company's new chief delivery officer following the acquisition of 180Commerce, a leading online sales partner.

Puccetti, who joins Cart.com from digital consultancy Blue Acorn, will manage all client deliverables for the company. Puccetti also previously served as general manager and senior vice president over e-commerce, strategym sales, and more at Onestop Internet.

"I've spent my career championing fast-growing brands in the retail space, so I recognized instantly that Cart.com's ability to deliver seamless end-to-end e-commerce support and services was a true gamechanger," Puccetti says in a news release. "I'm thrilled to be joining the team, and I'm looking forward to helping deliver the services and technologies that brands need to grow their business and realize their full potential in today's omnichannel world.

Cart.com hired Tony Puccetti as the company's new chief delivery officer. Photo via LinkedIn

Omair Tariq, Cart.com CEO, says Puccetti has the talent and experience the company's clients need.

"Cart.com has built a reputation for making big, bold promises — then delivering on them, and exceeding our customers' expectations as they scale their e-commerce brands," continues Tariq in the release. "We're delighted to be welcoming Tony to the Cart.com family, and we're looking forward to working with him to transform the tech-enabled commerce space for merchants of all sizes."

The news of Puccetti's appointment follows news of California-based 180Commerce's acquisition by Cart.com. The company was founded in 2016 following DSW's acquisition of Shoe Metro, the largest Amazon footwear reseller. According to the news release, leaders from Shoe Metro formed 180Commerce "to bring their expertise directly to brands through a tech-enabled agency service model." The company provides its clients with data-driven and tech-enabled retail strategies, tools, and resources.

"The 180Commerce value proposition has always focused on helping consumer brands grow long-term revenue and profitability by optimizing and streamlining their marketplace strategies. By joining with Cart.com, we're bringing that vision to a far wider audience while continuing to expand our offering to the brands we serve with the powerhouse of offerings Cart.com provides," says Jason Stuempfig, founder of 180Commerce. "We share Cart.com's vision for a no-hassle, fully integrated e-commerce ecosystem, and I'm delighted to be starting this new chapter in the 180Commerce story."

The acquisition means a merging of clients, services, and staff between the two companies. 180Commerce's full team will be onboarded to Cart.com under Stuempfig's leadership.

"We're thrilled to welcome the 180Commerce team into the Cart.com family as we continue to expand our offering of commerce everywhere," Tariq says in the release. "Jason turned 180Commerce into a success story by being relentlessly focused on delivering results for brands, while creating a powerful company culture in which everyone is valued. That's exactly the combination we look for at Cart.com — especially when it's paired with a commitment to using data and technology to streamline and optimize e-commerce and marketplace functions for fast-growing brands in every corner of the world."

This acquisition is the latest in a series for Cart.com. Previously, the company has acquired AmeriCommerce, Spacecraft Brands, DuMont Project, and Sauceda Industries.

"Acquisitions are central to Cart.com's growth strategy, and with the addition of 180Commerce we're underscoring our commitment to expanding into new areas and building out best-in-class capabilities across the full spectrum of e-commerce sales channels such as marketplaces," says Saheb Sabharwal, chief strategy officer at Cart.com, who leads all M&A activity, in the release. "We're looking forward to working with Jason and the 180Commerce team to drive new value for Cart.com's thousands of loyal users. We have a great process in place to integrate new companies into the Cart.com ecosystem, and we're actively seeking additional M&A opportunities as we augment our solutions for brands."

Remington Tonar, chief commercial officer and co-founder at Cart.com, also recently told InnovationMap of the company's plans on a recent episode of the Houston Innovators Podcast. Heading into the holidays, where potential new clients will be focusing on delivering on orders and sales, Tonar says Cart.com is expecting a busy 2022 in terms of growth. In a lot of ways, the COVID-19 pandemic played a major role in the development of e-commerce and, by extension, Cart.com.

"The pandemic has played a role in overall accelerating the growth of e-commerce as a category and an industry. That growth was going to happen anyways, but it made it more ubiquitous faster," Tonar says. "It's just commerce now. This is just how people purchase and consume things."

Stream the full podcast below.

Ad Placement 300x100
Ad Placement 300x600

CultureMap Emails are Awesome

UH research team receives grant to fight aggressive pediatric cancer

cancer research

Researchers at the University of Houston have received a $3.2 million grant from the National Institutes of Health to help find innovative ways to treat Rhabdomyosarcoma, or RMS.

According to a statement from the university, RMS is a malignant soft tissue sarcoma that has a higher incidence in young children and is responsible for 8 percent of pediatric cancer cases with a relatively low survival rate.

One way UH is working on the issue is by studying how and why RMS cells, which are found most often in muscle tissue, divide uncontrollably without ever maturing into normal muscle cells. The researchers aim to tackle a target inside RMS cells known as TAK1, which plays a key role in regulating cell growth.

“By targeting TAK1, we aim to stop the cancer at its source and help the cells develop normally,” Ashok Kumar, the Else and Philip Hargrove Endowed Professor of Drug Discovery at the UH College of Pharmacy and director of the Institute of Muscle Biology and Cachexia, said in a news release. “This approach could lead to new and better treatments for RMS.”

According to UH, preliminary results demonstrated that TAK1 is highly activated in embryonal RMS cells, which are found in younger children; alveolar RMS cells, which are found in older children and teens; and human RMS samples. This suggests that the protein plays a major role in the development of this form of cancer.

The team still aims to uncover how the protein helps RMS cancer grow and plans to evaluate how blocking TAK1 can be used as a therapeutic.

“Blocking TAK1, either by changing the genes (genetic approaches) or using drugs (pharmacological approaches), can stop certain harmful behaviors in cancer cells,” Kumar added. “This was tested both in lab-grown cells and in living models, showing that TAK1 is a key target to control RMS cancer’s spread and aggressiveness, and inhibits tumor formation.”

Texas A&M expands innovative Dog Aging Project via $7 million grant

pet project

The Texas A&M College of Veterinary Medicine and Biomedical Sciences has received a $7 million grant from the National Institutes of Health to support its Dog Aging Project.

The DAP is a research project that was launched in 2019 by Texas A&M and the University of Washington School of Medicine and has enrolled over 50,000 dogs to date, according to a release. The program studies various breeds of companion dogs and studies the effects of aging to help develop a better understanding of what can lead to an expanded, healthy canine life, which can also assist with human aging knowledge.

The NIH funds will be used to expand a clinical trial studying how the drug rapamycin, also called sirolimus, can extend the lives of companion dogs.

The project, known as Test of Rapamycin In Aging Dogs (TRIAD), is the third DAP clinical trial involving the drug rapamycin. The drug has previously been used as an immunosuppressant during organ transplants in humans. Past DAP studies reported that the drug appears to improve cardiac function in dogs.

“Rapamycin works by modifying the cells’ energy balance and energy handling,” Dr. Kate Creevy, DAP chief veterinary officer and a professor in the VMBS’ Department of Small Animal Clinical Sciences, said in a news release. "It seems to mimic the effects that happen in people or animals who do intermittent fasting. There is a lot of interest in intermittent fasting as a technique that can improve health, particularly healthy aging, and some of the pharmaceutical effects of rapamycin make the same changes at the cellular level.”

So far, 170 dogs are in the trial at 20 sites, with the goal of expanding to 580 dogs enrolled in multiple cities across the country. Dogs must be over 7 years old and in good general health to participate. They should also weigh at least 44 pounds. Owners are required to bring their dogs to one of TRIAD’s participating clinical sites every six months for three years. The Texas clinical sites are in College Station and North Texas.

“Dogs experience many of the age-related cognitive, sensory, neuropathologic and mobility changes that are common in older humans,” Dr. May Reed, a geriatrician at the University of Washington School of Medicine and another primary investigator in the study, said in the release. “The possibility that rapamycin might delay any of the alterations that contribute to cognitive impairment and functional decline is very exciting and has huge translational potential.”

“We get to learn how to support both dog and human aging at the same time. Our research is also powered by owners’ commitments to the health of their dogs, and that’s what makes our work both possible and meaningful,” Creevy added. “We’re very grateful to them.”

Houston unicorn startup named North American Company of the Year

top honor

Houston-based geothermal energy startup Fervo Energy has been named North American Company of the Year by research and consulting firm Cleantech Group.

Fervo appears on this year’s Global Cleantech 100, Cleantech Group’s annual list of the world’s most innovative and promising cleantech companies

Houston companies Syzygy Plasmonics and Vaulted Deep also made the Global Cleantech 100 list this year.

“These innovators give us reasons to be optimistic about the future. Their groundbreaking work demonstrates that progress toward net-zero remains possible and inspires us to double down on the challenge of addressing climate change,” says Richard Youngman, CEO of Cleantech Group.

Fervo was honored during a Jan. 27 awards dinner at Cleantech Forum North America, an event hosted by Cleantech Group. Co-founder and CEO Tim Latimer accepted the North American Company of the Year award on behalf of Fervo.

“We have always been honored to be part of the Global Cleantech 100,” Latimer says in a LinkedIn post. “Being recognized for the fourth consecutive year and named the ‘North American Company of the Year’ is a testament to our relentless pursuit of innovation in the energy sector. The demand for clean, firm power has never been more urgent, and we are proud to lead the way.”

Founded in 2017, Fervo is now a unicorn, meaning its valuation as a private company has surpassed $1 billion. The startup’s valuation is estimated at $1.4 billion. According to PitchBook data, the company raised $634 million in VC funding in Q4. Read more here.

--

This article originally appeared on our sister site, Energy Capital.